Mukul Agrawal stock jumps 14.2% after its net profit increases by 102.8% YoYMukul Agrawal stock jumps 14.2% after its net profit increases by 102.8% YoY

Introduction:

Leading pharma company reported a strong Q1 FY26 performance, with net profit rising 102.8% year-on-year to ₹10.8 crore, driven by improved margins, operational efficiency, and solid demand across key therapeutic and product segments.

Also Read: Electric equipment stock jumps after receiving ₹1349.11 Cr order from Adani Energy Solutions

Share price movement of Jagsonpal Pharmaceuticals:

On July 28, 2025, Jagsonpal Pharmaceuticals Ltd opened at ₹275.00, up 4.09% from its previous close of ₹264.20. The stock hit a high of ₹301.80 (14.22%) and a low of ₹269.30. By 4:01 PM, it traded at ₹292.55, marking a 10.73% gain, with a market cap of ₹1,946.23 crore.

Jagsonpal Pharma Q1 Profit Doubles YoY:

Jagsonpal Pharmaceuticals Ltd reported a net profit of ₹10.8 crore in Q1 FY26, marking a 102.8% year-on-year increase from ₹5.3 crore and a 63.5% rise from ₹6.6 crore sequentially.

Revenue for the quarter stood at ₹75.6 crore, up 23.1% compared to ₹61.4 crore in Q1 FY25 and a 29.1% increase over ₹58.6 crore reported in Q4 FY25.

Operating EBITDA reached ₹15.7 crore in Q1 FY26, growing 24.1% year-on-year from ₹12.7 crore and rising 61.9% quarter-on-quarter from ₹9.7 crore, reflecting improved operational efficiency and profitability.

Ace investor holding in Jagsonpal Pharmaceuticals:

Mukul Mahavir Agrawal

Mukul Mahavir Agrawal holds a 1.74% stake in Jagsonpal Pharmaceuticals Limited, owning 1,157,557 shares valued at ₹33.9 crore, reflecting his notable investment in the leading pharmaceutical company.

Stock performance of Jagsonpal Pharmaceuticals for Period of 1 week, 6 months, and 1 year:

Jagsonpal Pharmaceuticals Ltd delivered a 5.72% return over the past week and gained 9.23% in the past six months. The stock delivered an impressive 66.7% return over the past year.

Also Read: Tata group stock jumps after its net profits grow by 80.57% in Q1 FY26

Shareholding pattern of Jagsonpal Pharmaceuticals:

Particulars	Jun 2025	Mar 2025	Dec 2024
Promoter	67.70%	67.80%	67.80%
FII	2.20%	2.10%	2.10%
DII	0.10%	0.00%	0%
Public	30.10%	30.10%	30.10%

About Jagsonpal Pharmaceuticals:

Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM) is a leading pharma company with strong brands in gynaecology, orthopaedics, dermatology, and childcare, supported by a nationwide presence and a 1000+ member experienced sales team.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.